acquired
Stage
4
Investors
About
RayzeBio is a biotechnology company focused on developing targeted radiopharmaceutical drugs for solid tumors in cancers. The company utilizes an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis to prosecute diverse sets of binders against clinically validated cancer targets.
Explore rayzebio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.